Drug intelligence / Profile preview

YKYY025

Development stage: Phase 1
Lead developer: Yuekang Pharmaceutical
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

YKYY025 is an mRNA-based vaccine candidate developed by Beijing Yuekang Kechuang Pharmaceutical Technology and Hangzhou Tianlong Pharmaceutical for the prevention of respiratory syncytial virus (RSV) infection and associated lower respiratory tract disease. The vaccine utilizes messenger RNA technology to encode a specific RSV antigen, typically the fusion (F) protein, to elicit a protective immune response. It is currently being evaluated in Phase 1 clinical trials in adults to assess its safety, tolerability, and preliminary immunogenicity.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on YKYY025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YKYY025.

Explore the full profile